Related references
Note: Only part of the references are listed.Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
Annoek E. C. Broers et al.
BLOOD ADVANCES (2022)
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
Roni Shouval et al.
BLOOD ADVANCES (2022)
Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation
Remy Dulery et al.
JACC: CARDIOONCOLOGY (2021)
Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
Jason Yeh et al.
BLOOD ADVANCES (2021)
High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma
Mika Geva et al.
BONE MARROW TRANSPLANTATION (2021)
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon et al.
BLOOD (2020)
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Alexandros Spyridonidis et al.
BONE MARROW TRANSPLANTATION (2020)
Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation
Ivan Pasic et al.
ANNALS OF HEMATOLOGY (2020)
Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR
Jurjen Versluis et al.
SEMINARS IN HEMATOLOGY (2019)
Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision
Ashif Iqubal et al.
LIFE SCIENCES (2019)
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolanos-Meade et al.
LANCET HAEMATOLOGY (2019)
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
Giorgia Battipaglia et al.
BLOOD (2019)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers A Systematic Review and Meta-analysis
Nico Gagelmann et al.
JAMA ONCOLOGY (2019)
External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation
Roni Shouval et al.
BLOOD ADVANCES (2019)
Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality
Roni Shouval et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Poor performance of clinical prediction models: the harm of commonly applied methods
Ewout W. Steyerberg et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant
Annalisa Ruggeri et al.
HAEMATOLOGICA (2017)
Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant
Annalisa Ruggeri et al.
HAEMATOLOGICA (2017)
Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?
Rashmika Potdar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation
M. Mielcarek et al.
BLOOD (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
Karel G. M. Moons et al.
ANNALS OF INTERNAL MEDICINE (2015)
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
Stephen P. Hunger et al.
BLOOD (2015)
Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation
P. Barba et al.
BONE MARROW TRANSPLANTATION (2015)
Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation
Nick Beije et al.
HAEMATOLOGICA (2015)
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
Gary S. Collins et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
Gary S. Collins et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation
Nick Beije et al.
HAEMATOLOGICA (2015)
Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission
J. Versluis et al.
LEUKEMIA (2015)
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation
Pere Barba et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning
Christopher G. Kanakry et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Hematopoietic SCT in Europe: data and trends in 2011
J. R. Passweg et al.
BONE MARROW TRANSPLANTATION (2013)
T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Asad Bashey et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Jan J. Cornelissen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT
L. Castagna et al.
BONE MARROW TRANSPLANTATION (2011)
Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC
Pere Barba et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
Leo Luznik et al.
BLOOD (2010)
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Single and Multiple Institutions: Limitations and Inferences
Mohamed L. Sorror et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Keisuke Kataoka et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
Alois Gratwohl et al.
CANCER (2009)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Clinical pharmacokinetics of cyclophosphamide
ME de Jonge et al.
CLINICAL PHARMACOKINETICS (2005)
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide
PV O'Donnell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Share Paper
